Cardiac safety profile of prolonged (>or=6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies.

@article{Uyar2004CardiacSP,
  title={Cardiac safety profile of prolonged (>or=6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies.},
  author={Denise Uyar and Barbara Kulp and Gertrude Peterson and Kristine Zanotti and Maurie Markman and Jerome Leslie Belinson},
  journal={Gynecologic oncology},
  year={2004},
  volume={94 1},
  pages={147-51}
}
OBJECTIVE Pegylated liposomal doxorubicin (PLD) is currently utilized in the management of several solid tumors. While PLD has been shown to be less cardiotoxic than doxorubicin, the safety of prolonged administration (e.g., >or=6 cycles) of the agent remains undefined. METHODS A retrospective chart review was performed of the Cleveland Clinic experience from 1997 to 2003 with the prolonged (>or=6 cycles) use of PLD in individuals with gynecologic malignancies. PLD was administered at doses… CONTINUE READING